ArticleAmerican journal of hematology2015
MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ production.
Article in American journal of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Pre-transplant microRNA serum profiles and association with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2026Article
- Prediction of transplant rejection using non-coding RNAs.Molecular biology reports · 2025Review
- Review
- Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?Pharmaceuticals (Basel, Switzerland) · 2024Review
- Role of microRNAs in Immune Regulation with Translational and Clinical Applications.International journal of molecular sciences · 2024Review
- MYC-mediated silencing of miR-181a-5p promotes pathogenic Th17 responses by modulating AKT3-FOXO3 signaling.iScience · 2022Article
- MicroRNA-181a restricts human γδ T cell differentiation by targeting Map3k2 and Notch2.EMBO reports · 2022Article
- AKT Isoforms in the Immune Response in Cancer.Current topics in microbiology and immunology · 2022Article
- Circulating miR-455-3p, miR-5787, and miR-548a-3p as potential noninvasive biomarkers in the diagnosis of acute graft-versus-host disease: a validation study.Annals of hematology · 2021Article
- Amniotic membrane-mesenchymal stromal cells secreted factors and extracellular vesicle-miRNAs: Anti-inflammatory and regenerative features for musculoskeletal tissues.Stem cells translational medicine · 2021Article
- Profiling Tissue and Biofluid miR-155-5p, miR-155Frontiers in immunology · 2021Article
- Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role?Frontiers in immunology · 2021Review
- MicroRNAs in graft-versus-host disease: a review of the latest data.Bone marrow transplantation · 2020Review
- MicroRNA-181a regulates IFN-γ expression in effector CD8Journal of molecular medicine (Berlin, Germany) · 2020Article
- DNT Cell-based Immunotherapy: Progress and Applications.Journal of Cancer · 2020Review
- MicroRNAs as Immune Regulators of Inflammation in Children with Epilepsy.International journal of molecular and cellular medicine · 2020Article
- A panel of 4 biomarkers for the early diagnosis and therapeutic efficacy of aGVHD.JCI insight · 2019Article
- Control of Immunoregulatory Molecules by miRNAs in T Cell Activation.Frontiers in immunology · 2018Review
- The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.Frontiers in immunology · 2018Review
- Non-Coding RNA Mediated Regulation of Allogeneic T Cell Responses After Hematopoietic Transplantation.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Funding
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a valuable therapeutic strategy for a wide variety of diseases. Acute graft-versus-host disease (aGVHD) is a major complication in up to 75% of allo-HSCT. The absence of a reliable predicative marker for aGVHD onset prevents preemptive treatment and impedes widespread and successful application of this therapy. In this study we found that after allo-HSCT, the levels of miR-181a were reduced significantly prior to the onset of aGVHD. More importantly, the degree of its reduction correlated with the severity of aGVHD. Mechanistically, miR-181a affects the function of T lymphocytes by down-regulating IFN-γ in a dose-dependent manner. Meanwhile, we confirmed that miR-181a can effectively preserve the anti-leukemic effect in vitro. Using a murine allo-HSCT model, we demonstrated that murine miR-181b, the human miR-181a homolog, served as an effective predictor of aGVHD. Moreover, expression of this microRNA ameliorated the severity of aGVHD. Collectively, these results show that the level of miR-181a may serve as a reliable marker for the diagnosis and prognosis the onset of aGVHD. Am. J. Hematol. 90:998-1007, 2015. © 2015 Wiley Periodicals, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.